Correction to: Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma

Kremer, Veronika; Ligtenberg, Maarten A.; Zendehdel, Rosa; Seitz, Christina; Duivenvoorden, Annet; Wennerberg, Erik; Colón, Eugenia; Scherman-Plogell, Ann-Helén; Lundqvist, Andreas

doi:10.1186/s40425-017-0292-8

Cited by 6 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, an overexpression of CCR5, which is naturally relevant to recruit NK cells to infected lung tissues [ 48 , 49 ], was successfully used in a combination therapy with CCL5-armed oncolytic viruses to enhance their antitumor activity [ 50 ]. Another study showed that the restored expression of CXCR2, which is lost on NK cells during in vitro cultivation and in the blood of tumor patients, can enhance their infiltration [ 51 ]. These studies underline the stunning potential to enhance the efficacy of cell therapies by engineering immune cells with chemokine receptors.…”

Section: Introductionmentioning

confidence: 99%

Efficient Redirection of NK Cells by Genetic Modification with Chemokine Receptors CCR4 and CCR2B

Feigl

Stahringer

Peindl

et al. 2023

IJMS

View full text Add to dashboard Cite

Natural killer (NK) cells are a subset of lymphocytes that offer great potential for cancer immunotherapy due to their natural anti-tumor activity and the possibility to safely transplant cells from healthy donors to patients in a clinical setting. However, the efficacy of cell-based immunotherapies using both T and NK cells is often limited by a poor infiltration of immune cells into solid tumors. Importantly, regulatory immune cell subsets are frequently recruited to tumor sites. In this study, we overexpressed two chemokine receptors, CCR4 and CCR2B, that are naturally found on T regulatory cells and tumor-resident monocytes, respectively, on NK cells. Using the NK cell line NK-92 as well as primary NK cells from peripheral blood, we show that genetically engineered NK cells can be efficiently redirected using chemokine receptors from different immune cell lineages and migrate towards chemokines such as CCL22 or CCL2, without impairing the natural effector functions. This approach has the potential to enhance the therapeutic effect of immunotherapies in solid tumors by directing genetically engineered donor NK cells to tumor sites. As a future therapeutic option, the natural anti-tumor activity of NK cells at the tumor sites can be increased by co-expression of chemokine receptors with chimeric antigen receptors (CAR) or T cell receptors (TCR) on NK cells can be performed in the future.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficient Redirection of NK Cells by Genetic Modification with Chemokine Receptors CCR4 and CCR2B

Feigl

Stahringer

Peindl

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Given that CXCL5 which is a CXCR2 ligand that correlated with increasing infiltration of CXCR2+NK cells into RCC tumors, the study extended to generate CXCR2-transduced NK cells for enhanced tumor-homing properties that would be critical for future development of ACT targeting RCC and even other solid tumors. 73 A similar strategy was also explored in terms of improving the migratory capacity of NK cells by overexpressing CXCR4 in CAR-NK cells. NK cells with EGFR-targeting CAR with a DNAX-activation domain were co-engineered to express CXCR4 which in turn, responded to CXCL12-secreting glioblastoma tumors and resulted in complete remission of these tumor-bearing mice.…”

Section: Nks—‘off-the-shelf’ Therapeutics For Cancer Treatmentmentioning

confidence: 99%

Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer

Neo

Chong

et al. 2023

J Immunother Cancer

View full text Add to dashboard Cite

Cell therapy encompasses an expanding spectrum of cell-based regimes for the treatment of human ailments, such as the use of immune cells, in particular T cells, for combating tumors and the modulation of inflammatory immune responses. In this review, we focus on cell therapy in the immuno-oncology space, which is largely driven by interests and demands from the clinics for better solutions to target various hard-to-treat cancers. We discuss recent advances in various types of cell therapies, including T cell receptor-T cells, chimeric antigen receptor (CAR)-T cells, tumor-infiltrating lymphocytes and natural killer cells. Particularly, the present review focuses on the strategies to improve therapeutic responses by either enhancing tumor recognition or the resilience of infused immune cells within tumor microenvironment. Finally, we discuss the potential of other innate or innate-like immune cell types currently being explored as promising CAR-cell alternatives that seek to address the limitations of conventional adoptive cell therapies.

show abstract

“…For example, NK cells are electroporated with mRNA encoding the chemokine receptor CCR7 to increase migration to lymph nodes expressing the chemokine CCL19. 97 Additionally, NK cells transduced with a viral vector encoding CXCR2 exhibited better motility against renal cell carcinoma tumors expressing cognate ligands such as CXCL1, CXCL2, CXCL5, CXCL6, and CXCL8. 98 Even if the best CAR-NK cells can be created, they will always encounter a suppressive tumor microenvironment, which may be the biggest challenge.…”

Section: Challenges Aheadmentioning

confidence: 99%

Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies

Zhao,

Zhu,

Cai

et al. 2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

Adoptive cell immunotherapy (ACT) is an innovative promising treatment for tumors. ACT is characterized by the infusion of active anti-tumor immune cells (specific and non-specific) into patients to kill tumor cells either directly or indirectly by stimulating the body's immune system. The patient's (autologous) or a donor's (allogeneic) immune cells are used to improve immune function. Chimeric antigen receptor (CAR) T cells (CAR-T) is a type of ACT that has gained attention. T cells from the peripheral blood are genetically engineered to express CARs that rapidly proliferate and specifically recognize target antigens to exert its anti-tumor effects. Clinical application of CAR-T therapy for hematological tumors has shown good results, but adverse reactions and recurrence limit its applicability. Tumor infiltrating lymphocyte (TIL) therapy is effective for solid tumors. TIL therapy exhibits T cell receptor (TCR) clonality, superior tumor homing ability, and low targeted toxicity, but its successful application is limited to a number of tumors. Regardless, TIL and CAR-T therapies are effective for treating cancer. Additionally, CAR-natural killer (NK), CAR-macrophages (M), and TCR-T therapies are currently being researched. In this review, we highlight the current developments and limitations of several types of ACT.

show abstract

Correction to: Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma

Cited by 6 publications

References 1 publication

Efficient Redirection of NK Cells by Genetic Modification with Chemokine Receptors CCR4 and CCR2B

Efficient Redirection of NK Cells by Genetic Modification with Chemokine Receptors CCR4 and CCR2B

Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer

Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies

Contact Info

Product

Resources

About